169 related articles for article (PubMed ID: 31617269)
1. Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis.
Baker D; Pryce G; James LK; Schmierer K; Giovannoni G
Eur J Neurol; 2020 Feb; 27(2):221-228. PubMed ID: 31617269
[TBL] [Abstract][Full Text] [Related]
2. CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS.
Kumar G; Maria Z; Kohli U; Agasing A; Quinn JL; Ko RM; Zamvil SS; Axtell RC
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33649164
[TBL] [Abstract][Full Text] [Related]
3. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
Samy E; Wax S; Huard B; Hess H; Schneider P
Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
[TBL] [Abstract][Full Text] [Related]
4. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
6. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.
Huntington ND; Tomioka R; Clavarino C; Chow AM; Liñares D; Maña P; Rossjohn J; Cachero TG; Qian F; Kalled SL; Bernard CC; Reid HH
Int Immunol; 2006 Oct; 18(10):1473-85. PubMed ID: 16914508
[TBL] [Abstract][Full Text] [Related]
7. B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation.
Asplund Högelin K; Isac B; Khademi M; Al Nimer F
Clin Immunol; 2024 Jan; 258():109870. PubMed ID: 38101497
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
Ho S; Oswald E; Wong HK; Vural A; Yilmaz V; Tüzün E; Türkoğlu R; Straub T; Meinl I; Thaler F; Kümpfel T; Meinl E; Mader S
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36702538
[TBL] [Abstract][Full Text] [Related]
9. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.
Kaegi C; Steiner UC; Wuest B; Crowley C; Boyman O
Front Immunol; 2020; 11():433. PubMed ID: 32265917
[No Abstract] [Full Text] [Related]
11. Dual Role of B Cells in Multiple Sclerosis.
Kumar G; Axtell RC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768658
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
Miyazaki Y; Niino M; Takahashi E; Suzuki M; Mizuno M; Hisahara S; Fukazawa T; Amino I; Nakano F; Nakamura M; Akimoto S; Minami N; Fujiki N; Doi S; Shimohama S; Terayama Y; Kikuchi S
Clin Immunol; 2018 Feb; 187():95-101. PubMed ID: 29079163
[TBL] [Abstract][Full Text] [Related]
13. The BAFF / APRIL system as therapeutic target in multiple sclerosis.
Magliozzi R; Marastoni D; Calabrese M
Expert Opin Ther Targets; 2020 Nov; 24(11):1135-1145. PubMed ID: 32900236
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies targeting B-cells in multiple sclerosis.
Milo R
Autoimmun Rev; 2016 Jul; 15(7):714-8. PubMed ID: 26970489
[TBL] [Abstract][Full Text] [Related]
15. Combination of TACI-IgG and anti-IL-15 treats murine lupus by reducing mature and memory B cells.
Ma N; Xiao H; Marrero B; Xing C; Wang X; Zheng M; Han G; Chen G; Hou C; Shen B; Li Y; Wang R; Jiang Z
Cell Immunol; 2014; 289(1-2):140-4. PubMed ID: 24791699
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
Stohl W
Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
[TBL] [Abstract][Full Text] [Related]
17. The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity.
Hoffmann FS; Kuhn PH; Laurent SA; Hauck SM; Berer K; Wendlinger SA; Krumbholz M; Khademi M; Olsson T; Dreyling M; Pfister HW; Alexander T; Hiepe F; Kümpfel T; Crawford HC; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
J Immunol; 2015 Jan; 194(2):542-52. PubMed ID: 25505277
[TBL] [Abstract][Full Text] [Related]
18. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
19. A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells.
Hua C; Audo R; Yeremenko N; Baeten D; Hahne M; Combe B; Morel J; Daïen C
J Autoimmun; 2016 Sep; 73():64-72. PubMed ID: 27372914
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
Stohl W
Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
